G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of G1 Therapeutics stock in a transaction on Monday, November 5th. The stock was sold at an average price of $41.38, for a total value of $31,035.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ:GTHX opened at $45.67 on Friday. G1 Therapeutics Inc has a 52-week low of $18.03 and a 52-week high of $69.57. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -12.79 and a beta of 1.16.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. On average, equities research analysts expect that G1 Therapeutics Inc will post -2.64 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in GTHX. Cubist Systematic Strategies LLC grew its holdings in G1 Therapeutics by 484.5% during the first quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock valued at $104,000 after purchasing an additional 2,316 shares during the period. BNP Paribas Arbitrage SA grew its holdings in G1 Therapeutics by 58.4% during the first quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after purchasing an additional 1,045 shares during the period. Great West Life Assurance Co. Can grew its holdings in G1 Therapeutics by 148.3% during the second quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after purchasing an additional 1,560 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its holdings in G1 Therapeutics by 44.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after purchasing an additional 1,200 shares during the period. Finally, Strs Ohio grew its holdings in G1 Therapeutics by 78.3% during the second quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after purchasing an additional 1,800 shares during the period. 69.09% of the stock is owned by institutional investors and hedge funds.
GTHX has been the subject of several research analyst reports. Needham & Company LLC lifted their price objective on G1 Therapeutics to $76.00 and gave the stock a “buy” rating in a report on Tuesday, September 18th. BidaskClub lowered G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 27th. HC Wainwright reaffirmed a “buy” rating and issued a $79.00 price objective on shares of G1 Therapeutics in a report on Monday, September 17th. BTIG Research initiated coverage on G1 Therapeutics in a report on Monday, September 10th. They issued a “buy” rating and a $80.00 price objective for the company. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Thursday, August 9th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. G1 Therapeutics has a consensus rating of “Buy” and an average price target of $74.00.
COPYRIGHT VIOLATION WARNING: “G1 Therapeutics Inc (GTHX) VP Sells $31,035.00 in Stock” was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://transcriptdaily.com/2018/11/10/g1-therapeutics-inc-gthx-vp-sells-31035-00-in-stock.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.